Irish firm Nuritas lands €3m in funding to prevent diabetes
Irish biotech research and development firm Nuritas has secured funding for a product it says will prevent Type 2 diabetes.
The company has secured €3m in funding from the EU to support the final stage of development of a natural ingredient which the company says will prevent diabetes developing.
The funding will include Irish-based clinical trials which will take place over the next 18 months. If the trials are successful and the product gains approval, the new “peptide” could be used in food products across the EU by 2020.
Nuritas CEO, Emmet Browne, said: “This is a hugely important validation for Nuritas and our use of cutting-edge artificial intelligence driven technology to transform the future of disease prevention and food around the globe. While we have a rich pipeline of similar breakthrough peptides, all found from natural sources with amazing scientific potential, diabetes prevention now becomes Nuritas’ first important area of focus, with many more to follow.
This peptide carries huge potential to bridge an enormous gap in medical science and act as a major weapon in the global battle against diabetes, now recognised as a full blown epidemic.”